Literature DB >> 34532128

The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds.

Xiaohui Duan1, Yi Cai1, Tingting He2, Xiaoliang Shi2, Juan Zhao2, Hui Zhang1, Yao Shen1, Hongjian Zhang1, Heng Zhang1, Wenbin Duan1, Bo Jiang1, Xianhai Mao1.   

Abstract

BACKGROUND: Racial disparities in the survival of patients with hepatocellular carcinoma (HCC) exist. Gene mutations have a profound effect on carcinogenesis, are easily affected by environment and etiology factors, and may result in survival divergences among patients with different racial backgrounds. This report explores the effects of gene mutations on the survival of American Caucasians and Asian patients.
METHODS: The sequencing and clinical data of 336 HCC patients were obtained from The Cancer Genome Atlas (TCGA) database. The sequencing data was subject to gene mutation profiling, and an analysis of immune cell infiltration was conducted. A multivariate analysis was performed to assess the independent effects of gene mutations on patients' overall survival (OS) and disease-free survival (DFS).
RESULTS: Asian HCC patients had a significantly higher level of TP53 mutation frequency than Caucasian HCC patients (Asian vs. Caucasian, 39% vs. 23%; P=0.003). The TP53 mutation was associated with shorter OS [hazard ratio (HR), 2.33; 95% confidence interval (CI), 1.36-3.97; P=0.002] and DFS (HR, 2.2; 95% CI, 1.38-3.51; P<0.001) in Caucasian HCC patients, but had no effect on Asian HCC patients' survival. Compared to Asian HCC patients, Caucasian HCC patients with the TP53 mutation had a decreased proportion of infiltrating M2 macrophages and activating natural killer (NK) cells, and an increased proportion of follicular helper T cells. The RB1 mutation was associated with shorter OS (HR, 3.37; 95% CI, 1.73-6.57; P<0.001) in Asian HCC patients, and shorter DFS (HR, 2.11; 95% CI, 1.15-3.88; P=0.017) in Caucasian HCC patients. Asian HCC patients with the RB1 mutation had a decreased proportion of infiltrating CD8 T cells.
CONCLUSIONS: The effects of the TP53 and RB1 mutations on survival differ among Asian and Caucasian HCC patients. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  RB1; TP53; immune cells; race; survival

Year:  2021        PMID: 34532128      PMCID: PMC8421922          DOI: 10.21037/jgo-21-312

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  40 in total

1.  Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes.

Authors:  Masatsugu Yano; Kiyohiro Hamatani; Hidetaka Eguchi; Yuko Hirai; Donald G MacPhee; Keizo Sugino; Kiyohiko Dohi; Toshiyuki Itamoto; Toshimasa Asahara
Journal:  Eur J Cancer       Date:  2007-03-12       Impact factor: 9.162

2.  Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France.

Authors:  B Terris; P Laurent-Puig; J Belghitti; C Degott; D Hénin; J F Fléjou
Journal:  Int J Cancer       Date:  1997-12-19       Impact factor: 7.396

3.  Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.

Authors:  R-H Yuan; Y-M Jeng; H-L Chen; P-L Lai; H-W Pan; F-J Hsieh; C-Y Lin; P-H Lee; H-C Hsu
Journal:  J Pathol       Date:  2006-08       Impact factor: 7.996

Review 4.  The global epidemiology of hepatocellular carcinoma: present and future.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

5.  Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma.

Authors:  Zhao Zhang; Lijie Ma; Shyamal Goswami; Jiaqiang Ma; Bohao Zheng; Meng Duan; Longzi Liu; Lijun Zhang; Jieyi Shi; Liangqing Dong; Yumeng Sun; Lingyu Tian; Qiang Gao; Xiaoming Zhang
Journal:  Oncoimmunology       Date:  2019-02-07       Impact factor: 8.110

6.  The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas.

Authors:  H Sugo; S Takamori; K Kojima; T Beppu; S Futagawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

7.  Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma.

Authors:  N H Park; Y H Chung; K H Youn; B C Song; S H Yang; J A Kim; H C Lee; E Yu; Y S Lee; S G Lee; K W Kim; D J Suh
Journal:  J Clin Gastroenterol       Date:  2001 Nov-Dec       Impact factor: 3.062

8.  Identification of target genes of the p16INK4A-pRB-E2F pathway.

Authors:  Richard Vernell; Kristian Helin; Heiko Müller
Journal:  J Biol Chem       Date:  2003-08-15       Impact factor: 5.157

9.  p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.

Authors:  K Honda; E Sbisà; A Tullo; P A Papeo; C Saccone; S Poole; M Pignatelli; R R Mitry; S Ding; A Isla; A Davies; N A Habib
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

Review 10.  Putting p53 in Context.

Authors:  Edward R Kastenhuber; Scott W Lowe
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

View more
  1 in total

1.  DNA Damage Repair Classifier Defines Distinct Groups in Hepatocellular Carcinoma.

Authors:  Markia A Smith; Sarah C Van Alsten; Andrea Walens; Jeffrey S Damrauer; Ugwuji N Maduekwe; Russell R Broaddus; Michael I Love; Melissa A Troester; Katherine A Hoadley
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.